Bladder cancer cases to hit 340,000 by 2033

Older adults aged 60 and above make up about 87% of diagnosed cases.

Bladder cancer cases in eight major markets, including Japan and China, are projected to grow at an annual rate of 2.24%, rising from 280,0000 cases in 2023 to 340,000 in 2033, according to GlobalData. 

The US will have the highest number of diagnosed cases at approximately 100,000, whilst France will report the lowest at 20,000 for 2023.

Antara Bhattacharya, an associate project manager in GlobalData’s Epidemiology team, noted that men are more affected, comprising about 78% of cases, compared to 22% for women. Older adults aged 60 and above make up nearly 87% of diagnosed cases, with younger adults aged 18 to 59 accounting for about 13%.

Roughly 45% of bladder cancer cases were diagnosed in early stages, with severe cases making up only 6%. Furthermore, about 79% of cases were detected at early tumour stages, compared to 4% in more advanced stages. 

Bhattacharya attributed the high diagnosis rates to the increased use of cystoscopy, an invasive diagnostic procedure. However, even with early-stage diagnosis, relapse and recurrence remain common, affecting approximately 74% of cases.

Bladder cancer, the ninth most common type of cancer, poses challenges due to the cost and complexity of timely detection. Bhattacharya emphasised the need for comprehensive research and improved medical strategies to enhance early detection and treatment. 

Ongoing epidemiological studies focusing on stages of bladder cancer with a high likelihood of recurrence can contribute to better treatment outcomes. Effective treatment of bladder cancer involves a multi-pronged approach, combining medical and surgical care, lifestyle adjustments, continuous support, as well as advanced treatments like immunotherapy, targeted therapy, participation in clinical trials, and consistent follow-up.